GENELUX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 3.07 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-13
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 958.97K shares, a 429.84% increase year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-12-31 was 568.25K shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-09-30 was 180.99K shares, a 212.60% increase year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 960.47K shares, a 9.15% increase from fiscal 2024.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 879.93K shares, a 413.38% increase from fiscal 2023.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 171.40K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.07M shares 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 958.97K shares derived: sum of 2 quarters · filed 2026-03-19 | 960.47K shares 10-K · filed 2026-03-19 | |
| 2025-09-30 | 958.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 960.47K shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 1.50K shares 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | 568.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 749.24K shares derived: sum of 2 quarters · filed 2025-03-28 | 749.24K shares derived: sum of 3 quarters · filed 2025-03-28 | 879.93K shares 10-K · filed 2025-03-28 |
| 2024-09-30 | 180.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 180.99K shares derived: sum of 2 quarters · filed 2024-11-14 | 311.68K shares 10-Q · filed 2024-11-14 | 311.68K shares derived: sum of 4 quarters · filed 2025-03-28 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 130.69K shares 10-Q · filed 2024-08-14 | 130.69K shares derived: sum of 3 quarters · filed 2025-03-28 | 188.59K shares derived: sum of 4 quarters · filed 2025-03-28 |
| 2024-03-31 | 130.69K shares 10-Q · filed 2024-05-09 | 130.69K shares derived: sum of 2 quarters · filed 2025-03-28 | 188.59K shares derived: sum of 3 quarters · filed 2025-03-28 | 188.59K shares derived: sum of 4 quarters · filed 2025-03-28 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 57.90K shares derived: sum of 2 quarters · filed 2025-03-28 | 57.90K shares derived: sum of 3 quarters · filed 2025-03-28 | 171.40K shares 10-K · filed 2025-03-28 |
| 2023-09-30 | 57.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 57.90K shares derived: sum of 2 quarters · filed 2023-11-14 | 171.40K shares 10-Q · filed 2023-11-14 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 113.50K shares 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 113.50K shares 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |